LRMR (Larimar Therapeutics) חוב לטווח קצר להון

This chart of current Larimar Therapeutics (LRMR) quotes demonstrates the asset's dynamics, with a value of 0.01. Larimar Therapeutics is a pioneer in the therapy of rare genetic brain pathologies, creating proteins for targeted mitochondrial impact. The business relies on US-based R&D centers while outsourcing peptide production to external contractors. Meanwhile, research capacities are fully utilized, and partner plants consistently ensure the production of drugs for testing.

The ratio is calculated as the proportion of liabilities maturing within one year to total equity, reflecting the current debt load. This metric allows for an assessment of liquidity risk and the company's dependence on external financing in the short term. For Larimar Therapeutics (LRMR), whose biotechnological developments are independent of macroeconomic cycles, this parameter serves as an indicator of financial stability. Analyzing the level of short-term debt to equity helps identify fundamental bottom points.